Login to Your Account



Advantagene Gets SPA, Plans Prostate Vaccine Phase III Star

By Tom Wall


Friday, May 20, 2011
Having secured an agreement with the FDA on a special protocol assessment (SPA), Advantagene Inc. expects to initiate in mid-2011 a pivotal Phase III trial of lead candidate ProstAtak (AdV-tk) for patients with newly diagnosed prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription